Thymidylate synthase (TS) gene expression in primary lung cancer patients: A large-scale study in Japanese population

Annals of Oncology

Volumn 22, Issue 8, 2011, Pages 1791-1797

  Tanaka, F ^a   Wada, H ^b   Fukui, Y ^c   Fukushima, M ^c  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Lung cancer; Thymidylate synthase; TS

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; JAPANESE; LASER CAPTURE MICRODISSECTION; LUNG ADENOCARCINOMA; LUNG ALVEOLUS EPITHELIUM; LUNG CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; THYMIDYLATE SYNTHASE GENE; TUMOR CELL; TUMOR GROWTH;

EID: 79960987500     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq730     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 58: 71-96.
2. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004; 350: 379-392.
3. Carney DN, Hansen HH. Non-small-cell lung cancer-stalemate or progress. N Engl J Med 2000; 343: 1261-1262.
4. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346: 92-98.
5. Ohe Y, Ohashi Y, Kubota K et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooporative Study in Japan. Ann Oncol 2007; 18: 317-323.
6. Goffin J, Lacchetti C, Ellis PM et al. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer. J Thorac Oncol 2010; 5: 260-274.
7. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
8. Reck M, von Pawel J, Zantloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227-1234.
9. Shepherd FA, Pereira JR, Ciuleanu T et al. Erlotinib in previously treated nonsmall-cell lung cancer. N Engl J Med 2005; 353: 123-132.
10. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
11. Mistudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol 2010; 11: 121-128.
12. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597.
13. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
14. Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomized, double-blind, phase 3 study. Lancet 2009; 374: 1432-1440.
15. Kawahara M, Furuse K, Segawa Y et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 2001; 85: 939-943.
16. Ichinose Y, Yoshimori K, Sakai H et al. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multiinstitutional phase II study. Clin Cancer Res 2005; 10: 7860-7864.
17. Shih C, Chen VJ, Gossetti LS et al. LY231514, a pyrrolo [2,3-d] pyrimidinebased antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997; 57: 1116-1123.
18. Shultz RM, Patel VF, Worzalla JF et al. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res 1999; 19(1A): 437-443.
19. Giovannetti E, Backus HH, Wouters D et al. Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. Br J Cancer 2007; 96: 769-775.
20. Ozasa H, Oguri T, Uemura T et al. Significance of thymidylate synthase for resistance to pemetrexed in lung cancer. Cancer Sci 2010; 101: 161-166.
21. Gomez HL, Santillana SL, Vallejos CS et al. A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression. Clin Cancer Res 2006; 12: 832-838.
22. Rose MG, Farrell MP, Schmitz JC. Thymidylate synthase: a critical target for cancer chemotherapy. Clin Colorectal Cancer 2002; 1: 220-229.
23. Righi L, Papotti MG, Ceppi P et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 2010; 28: 1534-1539.
24. Socinski MA, Raju RN, Neubauer N et al. Pemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial. J Thorac Oncol 2008; 3: 1308-1316.
25. Jalal S, Ansari R, Govindan R et al. Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study. J Thorac Oncol 2009; 4: 93-96.
26. Gronberg BH, Bremners RM, Asaebo U et al. A prospective phase II study: highdose pemetrexed as second-line chemotherapy for small-cell lung cancer. Lung Cancer 2009; 63: 88-93.
27. Scagliotti G, Hanna N, Fossella F et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009; 14: 253-263.
28. Syrigos KN, Vansteenkiste J, Parikh P et al. Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatingemcitabine in advanced non-small-cell lung cancer. Ann Oncol 2010; 21: 556-561.
29. Ceppi P, Volante M, Saviozzi S et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006; 107: 1589-1596.
30. Monica V, Scagliotti GV, Ceppi P et al. Differential thymidylate synthase expression in different variants of large-cell carcinoma of the lung. Clin Cancer Res 2009; 15: 7547-7552.
31. Shirasaka T, Nakano K, Takechi T et al. Antitumor activity of 1M tegafur-0.4M 5-chloro-2,4-hydroxypyridine-1M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996; 56: 2602-2606.
32. Tanaka F, Wada H, Fukushima M. UFT and S-1 for treatment of primary lung cancer. Gen Thorac Cardiovasc Surg 2010; 58: 3-13.
33. Hamada C, Tanaka F, Ohta M et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 2005; 23: 4999-5006.
34. Huang C, Liu D, Masuya D et al. Clinical application of biological markers for treatment of resectable non-small-cell lung cancer. Br J Cancer 2005; 92: 1231-1239.
35. Ishihama H, Chida M, Araki O et al. Comparison of 5-fluorouracil-related gene expression levels between adenocarcinoma and squamous cell carcinoma of the lung. Jpn J Clin Oncol 2009; 39: 33-36.
36. Fukui Y, Oka T, Nagayama S et al. Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. Int J Mol Med 2008; 22: 709-716.
37. Otake Y, Tanaka F, Yanagihara K et al. Expression of thymidylate synthase in human non-small cell lung cancer. Jpn J Cancer Res 1999; 90: 1248-1253.
38. Nakagawa T, Tanaka F, Otake Y et al. Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung. Lung Cancer 2002; 35: 165-170.
39. Nakagawa T, Otake Y, Yanagihara K et al. Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer. Lung Cancer 2004; 43: 145-149.
40. Yamamoto N, Yamanaka T, Ichinose Y et al. Pooled analysis of S-1 trials in nonsmall cell lung cancer according to histological type. Anticancer Res 2010; 30: 2985-2990.